Evidence map›Paper›PMID 42185686›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Identification of a putative founder effect involving the HACE1:c.1396C>T variant in two Iranian families and review of reported cases.

Mohammad Dehani, Elham Pourbakhtyaran, Nooshin Goudarzi, Mir Salar Kahaei, Mohammad Miryounesi, Amin Ardeshirdavani, Majid Kabuli, Elia Damavandi, Reza Shervin Badv, Mohsen Ghadami and 1 more

Abstract readReviewCase Reports
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohammad Dehani *Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Elham Pourbakhtyaran *Department of Pediatric Neurology, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Nooshin GoudarziStudent Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.
Mir Salar KahaeiDepartment of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad MiryounesiDepartment of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amin ArdeshirdavaniCimorgh Medical IT Solutions, Tehran, Iran.
Majid KabuliDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Elia DamavandiDepartment of Photodynamic, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran.
Reza Shervin BadvChildren's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran. Drbadv@gmail.com.
Mohsen GhadamiDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. mghadami@tums.ac.ir.
Ali Rashidi-NezhadMaternal, Fetal and Neonatal Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran. arashidinezhad@tums.ac.ir.ORCID http://orcid.org/0000-0002-7200-7901

Funding

Tehran University of Medical Sciences and Health Services 67978Tehran University of Medical Sciences and Health Services 71512
6 · The paper itself

Abstract

backgroundBiallelic pathogenic variants in the HACE1 gene cause the ultra-rare neurodevelopmental disorder, Spastic Paraplegia and Psychomotor Retardation with or without Seizures (SPPRS). We identified a recurrent HACE1 variant in two unrelated, consanguineous Iranian families and investigated its potential founder origin, alongside a review of all reported HACE1-related cases.

methodsWhole exome sequencing (WES) was performed on the probands, and the variant was confirmed and segregated by Sanger sequencing. To assess a shared ancestral origin, we conducted runs of homozygosity (ROH) mapping, haplotype analysis, and mutation age estimation.

resultsBoth probands carried the same homozygous nonsense variant HACE1 (NM_020771.4:c.1396 C > T; p.Gln466Ter), which co-segregated with the disease in both families. ROH and haplotype analyses revealed a shared ~ 6.6 Mb homozygous region encompassing HACE1, consistent with a possible founder effect. The variant was estimated to have arisen approximately 10.3 generations ago (~ 250 years). Furthermore, review of previously reported HACE1-related cases indicated that delayed psychomotor development, intellectual disability, hypotonia, spasticity, brain abnormalities, motor disorders, and speech impairment are the most prevalent features.

conclusionOur findings support a putative founder effect, suggesting that the HACE1:c.1396C> T variant likely represents a founder variant within the Iranian population and, to our knowledge, mark the first report of SPPRS-causing variants from Iran. Beyond expanding the known genetic spectrum, this study highlights phenotypic heterogeneity, even among patients sharing the same genotype, and further characterizes the clinical variability and phenotypic spectrum of the disorder, thereby aiding more accurate diagnosis and genetic counseling for at-risk families.

Indexed as

Founder EffectUbiquitin-Protein LigasesChildConsanguinityExome SequencingFemaleHumansIranMalePedigreeUbiquitin-Protein LigasesFounder effectHACE1IranSpasticitySpastic paraplegia and psychomotor retardation with or without seizures (SPPRS)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.